Amendment No. 1 to the Controlled Equity OfferingSM Sales AgreementControlled Equity Offeringsm Sales Agreement • May 25th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) is effective as of March 22, 2018 (the “Amendment Date”), and modifies the Controlled Equity OfferingSM Sales Agreement, dated June 12, 2015 (the “Sales Agreement”), by and between Cantor Fitzgerald & Co. (“CF&Co”) and OncoMed Pharmaceuticals, Inc. (“OncoMed”). OncoMed and CF&Co are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms not defined herein shall have the meanings ascribed to them in the Sales Agreement.
